SIRT2 deficiency modulates macrophage polarization and susceptibility to experimental colitis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Lo Sasso, Giuseppe ^a   Menzies, Keir Joe ^a   Mottis, Adrienne ^a   Piersigilli, Alessandra ^a,b   Perino, Alessia ^a   Yamamoto, Hiroyasu ^a,c   Schoonjans, Kristina ^a   Auwerx, Johan ^a  

^a EPFL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; HISTONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR; CD69 ANTIGEN; CYTOKINE; LECTIN; LEUKOCYTE ANTIGEN; SIRT2 PROTEIN, MOUSE; T LYMPHOCYTE ANTIGEN;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; DEACETYLATION; DISEASE PREDISPOSITION; EXON; EXPERIMENTAL COLITIS; GENE DELETION; GENETIC CODE; HISTOPATHOLOGY; HOMOLOGOUS RECOMBINATION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; POLARIZATION; PROTEIN DEFICIENCY; WILD TYPE; ANIMAL; BLOOD; BONE MARROW CELL; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL POLARITY; CHEMICALLY INDUCED; COLITIS; COLON; CYTOLOGY; DEFICIENCY; DISEASE MODEL; FEMALE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPH NODE; METABOLISM; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELL POLARITY; CELLS, CULTURED; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; FEMALE; LECTINS, C-TYPE; LYMPH NODES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; SEVERITY OF ILLNESS INDEX; SIRTUIN 2;

EID: 84905027793     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103573     Document Type: Article

References (31)

1. Loftus EV (2004) Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 126: 1504-1517.
2. Ko Y, Butcher R, Leong RW (2014) Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases. World journal of gastroenterology : WJG 20: 1238-1247.
3. Sartor RB (2006) Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nature clinical practice Gastroenterology & hepatology 3: 390-407.
4. Rothgiesser KM, Erener S, Waibel S, Luscher B, Hottiger MO (2010) SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310. J Cell Sci 123: 4251-4258.
5. Pais TF, Szego{combining double acute accent} ÉM, Marques O, Miller-Fleming L, Antas P, et al. (2013) The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation. The EMBO Journal 32: 2603-2616.
6. Lin J, Sun B, Jiang C, Hong H, Zheng Y (2013) Sirt2 suppresses inflammatory responses in collagen-induced arthritis. Biochem Biophys Res Commun 441: 897-903.
7. Kim MJ, Kim DW, Park JH, Kim SJ, Lee CH, et al. (2013) PEP-1-SIRT2 inhibits inflammatory response and oxidative stress-induced cell death via expression of antioxidant enzymes in murine macrophages. Free radical biology & medicine 63: 432-445.
8. Houtkooper RH, Pirinen E, Auwerx J (2012) Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 13: 225-238.
9. Imai SI, Guarente L (2014) NAD and sirtuins in aging and disease. Trends Cell Biol.
10. Vaquero A, Scher MB, Lee DH, Sutton A, Cheng HL, et al. (2006) SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev 20: 1256-1261. (Pubitemid 43727586)
11. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E (2003) The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11: 437-444. (Pubitemid 36293837)
12. Bonizzi G, Bebien M, Otero DC, Johnson-Vroom KE, Cao Y, et al. (2004) Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J 23: 4202-4210. (Pubitemid 39546158)
13. Wirtz S, Neufert C, Weigmann B, Neurath MF (2007) Chemically induced mouse models of intestinal inflammation. Nat Protoc 2: 541-546. (Pubitemid 47040018)
14. Beirowski B, Gustin J, Armour SM, Yamamoto H, Viader A, et al. (2011) Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling. Proc Natl Acad Sci U S A 108: E952-961.
15. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, et al. (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702. (Pubitemid 20069706)
16. Cario E, Gerken G, Podolsky DK (2007) Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 132: 1359-1374. (Pubitemid 46627595)
17. Cooper HS, Murthy SN, Shah RS, Sedergran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249.
18. Cader MZ, Kaser A (2013) Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 62: 1653-1664.
19. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, et al. (1986) Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 105: 883-885. (Pubitemid 17201765)
20. Kucharzik T, Walsh SV, Chen J, Parkos CA, Nusrat A (2001) Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol 159: 2001-2009. (Pubitemid 33104255)
21. Suzuki T (2013) Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci 70: 631-659.
22. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122: 787-795.
23. Lawrence T, Natoli G (2011) Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 11: 750-761.
24. Hoesel B, Schmid JA (2013) The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 12: 86.
25. Melgar S, Karlsson L, Rehnstrom E, Karlsson A, Utkovic H, et al. (2008) Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease. Int Immunopharmacol 8: 836-844.
26. Zigmond E, Jung S (2013) Intestinal macrophages: well educated exceptions from the rule. Trends Immunol 34: 162-168.
27. Martinez FO, Helming L, Gordon S (2009) Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 27: 451-483.
28. Weiss L, Haeffner-Cavaillon N, Laude M, Cavaillon JM, Kazatchkine MD (1989) Human T cells and interleukin 4 inhibit the release of interleukin 1 induced by lipopolysaccharide in serum-free cultures of autologous monocytes. Eur J Immunol 19: 1347-1350. (Pubitemid 19196919)
29. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174: 1209-1220.
30. Pauleau AL, Rutschman R, Lang R, Pernis A, Watowich SS, et al. (2004) Enhancer-mediated control of macrophage-specific arginase I expression. J Immunol 172: 7565-7573. (Pubitemid 38747620)
31. Donnelly RP, Crofford LJ, Freeman SL, Buras J, Remmers E, et al. (1993) Tissue-specific regulation of IL-6 production by IL-4. Differential effects of IL-4 on nuclear factor-kappa B activity in monocytes and fibroblasts. J Immunol 151: 5603-5612. (Pubitemid 23332370)